Alumis Inc (ALMS)

Apr 21, 2025, 6:30 AM EDT - 2 days ago

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 16, 2025, 5:31 PM EDT - 7 days ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Apr 14, 2025, 10:02 AM EDT - 9 days ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Apr 7, 2025, 11:23 AM EDT - 16 days ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Apr 4, 2025, 4:34 PM EDT - 19 days ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Mar 25, 2025, 2:30 AM EDT - 4 weeks ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 19, 2025, 4:05 PM EDT - 5 weeks ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 10, 2025, 8:00 AM EDT - 6 weeks ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 8, 2025, 9:00 AM EST - 6 weeks ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 4, 2025, 9:01 AM EST - 7 weeks ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:00 AM EST - 7 weeks ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Feb 28, 2025, 9:08 AM EST - 7 weeks ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 27, 2025, 4:15 PM EST - 7 weeks ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 10, 2025, 4:45 PM EST - 2 months ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 7, 2025, 3:22 PM EST - 2 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Feb 6, 2025, 4:15 PM EST - 2 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Jan 28, 2025, 8:00 AM EST - 3 months ago

Alumis Strengthens Leadership Team with Key Appointments

Nov 13, 2024, 4:05 PM EST - 5 months ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Oct 17, 2024, 2:32 PM EDT - 6 months ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Oct 4, 2024, 2:00 AM EDT - 7 months ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Sep 27, 2024, 9:00 AM EDT - 7 months ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 16, 2024, 4:32 PM EDT - 7 months ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 3, 2024, 4:29 PM EDT - 8 months ago

Alumis to Participate in Upcoming September Investor Conferences

Aug 13, 2024, 4:05 PM EDT - 9 months ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Jul 29, 2024, 8:00 AM EDT - 9 months ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 24, 2024, 3:18 PM EDT - 9 months ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 1, 2024, 11:51 AM EDT - 10 months ago

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

AGH INHI LB LINE TBN TWFG WBTN

Jun 28, 2024, 1:36 PM EDT - 10 months ago

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Jun 28, 2024, 12:58 PM EDT - 10 months ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:43 AM EDT - 10 months ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 27, 2024, 11:57 PM EDT - 10 months ago

Alumis Announces Pricing of Initial Public Offering

Jun 24, 2024, 8:27 AM EDT - 10 months ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 7:18 AM EDT - 10 months ago

Alumis eyes $300 million in proceeds in IPO

Jun 11, 2024, 12:25 PM EDT - 11 months ago

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results